Advances in achieving opioid analgesia without side effects by Machelska, Halina & Celik, Melih Ö.
fphar-09-01388 November 28, 2018 Time: 17:7 # 1
REVIEW




UPR3212 Institut des Neurosciences
Cellulaires et Intégratives (INCI),
France
Reviewed by:
Anna M. W. Taylor,
University of Alberta, Canada
Theodore John Price,






This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 20 September 2018
Accepted: 12 November 2018
Published: 29 November 2018
Citation:
Machelska H and Celik MÖ (2018)
Advances in Achieving Opioid
Analgesia Without Side Effects.
Front. Pharmacol. 9:1388.
doi: 10.3389/fphar.2018.01388
Advances in Achieving Opioid
Analgesia Without Side Effects
Halina Machelska* and Melih Ö. Celik
Department of Experimental Anesthesiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität
Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
Opioids are the most effective drugs for the treatment of severe pain, but they also
cause addiction and overdose deaths, which have led to a worldwide opioid crisis.
Therefore, the development of safer opioids is urgently needed. In this article, we
provide a critical overview of emerging opioid-based strategies aimed at effective
pain relief and improved side effect profiles. These approaches comprise biased
agonism, the targeting of (i) opioid receptors in peripheral inflamed tissue (by reducing
agonist access to the brain, the use of nanocarriers, or low pH-sensitive agonists); (ii)
heteromers or multiple receptors (by monovalent, bivalent, and multifunctional ligands);
(iii) receptor splice variants; and (iv) endogenous opioid peptides (by preventing their
degradation or enhancing their production by gene transfer). Substantial advancements
are underscored by pharmaceutical development of new opioids such as peripheral
κ-receptor agonists, and by treatments augmenting the action of endogenous opioids,
which have entered clinical trials. Additionally, there are several promising novel opioids
comprehensively examined in preclinical studies, but also strategies such as biased
agonism, which might require careful rethinking.
Keywords: opioid receptor signaling, opioid side effects, addiction, pain, peripheral opioid analgesia, biased
agonists, heteromers, endogenous opioid peptides
INTRODUCTION
Opioids relieve pain, but also produce numerous side effects. All actions of opioids are mediated
by µ-, δ-, and κ-opioid receptors encoded by the three respective genes (Evans et al., 1992; Kieffer
et al., 1992; Mestek et al., 1995; Simonin et al., 1995). Opioid receptors belong to the superfamily
of guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) and their structures
have been solved at high-resolution by X-ray crystallography (Granier et al., 2012; Huang et al.,
2015; Che et al., 2018). Upon activation by an agonist, opioid receptors couple to pertussis toxin-
sensitive heterotrimeric Gi/o proteins, which dissociate into Gαi/o and Gβγ subunits to interact
with various intracellular effector systems (Law et al., 2000; Waldhoer et al., 2004; Stein, 2016).
Gαi/o inhibits adenylyl cyclases (AC), cyclic adenosine monophosphate (cAMP) formation, and
protein kinase A (PKA) activity, which leads to the blockade of a heat sensor transient receptor
potential cation channel subfamily V member 1 (TRPV1) (Vetter et al., 2006; Endres-Becker
et al., 2007). Gαi/o–cAMP pathway also suppresses hyperpolarization-activated cyclic nucleotide-
gated (HCN) channels, acid-sensing ion channels (ASIC), and voltage-gated Na+ (Nav) channels
(Ingram and Williams, 1994; Gold and Levine, 1996; Cai et al., 2014). Gβγ blocks voltage-gated
Ca2+ (Cav) channels and heat-sensing transient receptor potential cation channel subfamily M
member 3 (TRPM3), and activates various K+ channels such as G protein-coupled inwardly
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rectifying K+ (GIRK or Kir3) channels and adenosine
triphosphate-sensitive K+ (KATP) channels (Law et al.,
2000; Waldhoer et al., 2004; Cunha et al., 2010; Stein, 2016;
Dembla et al., 2017). Ultimately, these opioid-mediated
actions lead to the suppression of excitatory neurotransmitter
release (e.g., substance P, calcitonin gene-related peptide,
glutamate), hyperpolarization and an overall decrease in
neuronal excitability, which culminates in analgesia (Yaksh,
1997; Ocaña et al., 2004; Stein, 2016; Yudin and Rohacs, 2018)
(Figure 1A). Additionally, analgesia can be mediated by opioid
receptors expressed in immune cells. Activation of leukocyte
opioid receptors leads to the secretion of endogenous opioid
peptides (β-endorphin, Met-enkephalin, and dynorphin A
1-17), which involves Gαi/o–Gβγ–phospholipase C (PLC)–
inositol 1,4,5-trisphosphate receptor (IP3R)– intracellular Ca2+
pathway. The released opioid peptides subsequently activate
neuronal opioid receptors and alleviate pain (Celik et al., 2016)
(Figure 1B).
Opioid receptors also mediate numerous adverse effects that
limits opioid pain therapy. Activation of µ-receptors can lead to
respiratory depression, sedation, constipation, nausea, vomiting,
reward/euphoria, and dependence/withdrawal. Activation of
δ-receptors can cause convulsions and may produce reward
or contribute to rewarding effects of other drugs of abuse.
Agonists of κ-receptors exert aversion/dysphoria, sedation, and
diuresis (i.e., increased urine output). Each of these symptoms
represents a complex phenomenon with multiplex cellular and
molecular mechanisms (Kapusta, 1995; Li and van den Pol,
2008; Bruijnzeel, 2009; Koob and Volkow, 2010; Gendron
et al., 2016; Dripps et al., 2018). Importantly, these side
effects are brought about by G protein-mediated actions in
response to opioid receptor activation (Figure 2A). Opioid-
induced respiratory depression is mediated by Gβγ-dependent
activation of GIRK channels, which results in inhibition of
neurons in the brainstem respiratory center (Montandon et al.,
2016). Sedation is a consequence of the suppression of neurons
in the hypothalamic arousal system, which depends on Gβγ
actions on GIRK and Cav channels (Li and van den Pol,
2008). Constipation results from Gβγ-mediated activation of
GIRK channels and inhibition of Cav channels leading to the
suppression of enteric neuronal activity, including acetylcholine
and substance P secretion blockade in the gastrointestinal tract
(Galligan and Akbarali, 2014). Indirect evidence suggests that
nausea and vomiting may involve Gαi/o-mediated decrease of
the cAMP–PKA pathway activity, blockade of Cav channels
and thus, inhibition of neurons in the vestibular apparatus
(Seseña et al., 2014; Imam et al., 2017). Opioid-induced diuresis
results from the inhibition of arginine vasopressin secretion
in the hypothalamus, suggestive of G protein involvement,
although the exact signaling pathways have not been elucidated
(Kapusta, 1995). Chronic opioid use leads to Gβγ–cAMP–
PKA pathway activation resulting in enhanced activity of ion
channels (e.g., Nav channels) and receptors (e.g., dopamine and
N-methyl-D-aspartic acid receptors) and thereby, in increased
neuronal activity (Nestler and Aghajanian, 1997; Liu and Anand,
2001; Christie, 2008). Furthermore, prolonged activation of
opioid receptors results in Gβγ-dependent activation of protein
kinase C (PKC), Ca2+/calmodulin-dependent protein kinase
(CaMK) II, and extracellular signal-regulated kinases 1 and
2 of the mitogen-activated protein kinases (MAPKs). These
kinases as well as PKA can phosphorylate opioid receptors,
which results in their uncoupling from G protein-mediated
effects (Liu and Anand, 2001; Christie, 2008; Al-Hasani and
Bruchas, 2011). These events have been ascribed to alterations
in opioid receptor signaling underlying analgesic tolerance,
reward/euphoria, dependence/withdrawal, or aversion/dysphoria
(Nestler and Aghajanian, 1997; Law et al., 2000; Liu and
Anand, 2001; Waldhoer et al., 2004; Christie, 2008; Koob
and Volkow, 2010; Al-Hasani and Bruchas, 2011; Gendron
et al., 2016) (Figure 2A). Additionally, opioid receptors are
phosphorylated by GPCR kinases (GRKs), which is followed
by recruitment of β-arrestins (Figure 2B). This process occurs
after even brief agonist exposure and it terminates G protein
coupling and signaling to promote receptor desensitization
and internalization. Dephosphorylated opioid receptors can be
recycled to the plasma membrane, which reinstates signaling,
or can be targeted to lysosomes and degraded (Waldhoer et al.,
2004). β-arrestin-2 (also known as arrestin-3) might be involved
in morphine-induced analgesic tolerance, respiratory depression,
and constipation (Bohn et al., 2000; Raehal et al., 2005). It has
also been proposed to mediate κ-receptor-induced aversion via
activation of p38 MAPK (Bruchas et al., 2006; Land et al., 2009;
Ehrich et al., 2015). Nevertheless, the exact β-arrestin-2-regulated
signaling underlying opioid-induced side effects are yet unclear
(Figure 2B). The cellular mechanisms of δ-receptor-mediated
convulsions have not been identified, and do not seem to involve
Gαo or β-arrestin-2 (Dripps et al., 2018).
Clearly, conventional opioids produce numerous side effects,
yet they are the strongest painkillers. As all other, non-opioid
pain medications also exert adverse actions, none of them
produces as powerful pain relief as opioids (Stein and Kopf, 2009;
Sondergaard and Gislason, 2017; Welsch et al., 2018). Therefore,
opioids will remain the main therapy for moderate and severe
pain, which makes efforts to improve their action profile highly
desirable and relevant. In the following sections, we present
several interesting strategies to achieve safer opioid analgesia, and
discuss limitations associated with these new approaches.
TARGETING OPIOID RECEPTORS IN
PAINFUL TISSUE
The Rationale
All three opioid receptors (µ, δ, and κ) are expressed in the central
nervous system (CNS), including spinal cord and brain, as well
as in peripheral sensory neurons (nociceptors). Peripheral opioid
receptors are synthetized in nociceptor cell bodies in trigeminal
and dorsal root ganglia (DRG), from where they are transported
and accumulate in nociceptor peripheral terminals innervating
peripheral tissue (skin, joints, viscera) (Figures 1B, 3A). The
concept of targeting peripheral opioid receptors comes from the
fact that they mediate effective analgesia, but are not involved in
fatal effects, in animal models and in humans (Kalso et al., 2002;
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FIGURE 1 | Mechanisms of opioid-induced analgesia. (A) Cellular effects mediated by neuronal opioid receptors (OR). Activation of OR by an opioid leads to the
dissociation of Gi/o proteins into Gαi/o and Gβγ subunits (step 1). Gαi/o inhibits AC, cAMP formation, and PKA activity, which blocks various ion channels, including
TRPV1, HCN, ASIC, and Nav channels (path 2). Gβγ blocks Cav and TRPM3 channels (path 3), and activates GIRK and KATP channels (path 4). Ultimately, these
actions lead to the decrease in neuronal excitability, which culminates in analgesia. (B) Cellular effects mediated by OR in immune cells. Activation of leukocyte
Gi/o-coupled OR leads to the Gβγ-mediated activation of PLC and production of IP3, which activates IP3R in endoplasmic reticulum (ER) to release intracellular
Ca2+, which results in the secretion of opioid peptides from immune cells. The released opioid peptides activate neuronal OR and decrease pain.
Stein et al., 2003; Stein and Machelska, 2011; Sawynok and Liu,
2014). Indeed, the serious side effects arise from opioid actions
in the brain (Figure 3B). Respiratory depression results from
activation of µ-receptors in the brainstem medulla (preBötzinger
complex) and pons (Kölliker-Fuse nucleus, parabrachial nuclei,
locus coeruleus), in cortical areas, thalamus, and amygdala, and
to a lesser extent in the periphery in the carotid body (Pattinson,
2008; Imam et al., 2017). Reward and dependence/withdrawal
mediated by µ-receptors, as well as aversion/dysphoria mediated
by κ-receptors involve a widely distributed brain network,
including the mesolimbic pathway (ventral tegmental area,
nucleus accumbens), amygdala, cortex, hippocampus, and insula
(Bruijnzeel, 2009; Koob and Volkow, 2010). Sedation is caused
by µ- and κ-receptor activation in the hypothalamic and locus
coeruleus neurons controlling arousal and sleep (Greco et al.,
2008; Li and van den Pol, 2008; Chung et al., 2017). Convulsive
actions of δ-receptor agonists involve hippocampus and thalamo-
cortical circuits (Jutkiewicz et al., 2006). Constipation is mostly
mediated by µ-receptors in peripheral sensory myenteric and
submucosal neurons in the gastrointestinal tract, but spinal and
supraspinal receptors may also be involved (Burks, 1990; Galligan
and Akbarali, 2014; Imam et al., 2017). Nausea and vomiting
are mostly mediated by µ-receptors in the medulla, cortex,
and vestibular apparatus, and partially in the gastrointestinal
tract, possibly secondary to constipation (Porreca and Ossipov,
2009; Imam et al., 2017). Diuresis results from activation of
κ-receptors in the hypothalamus with some actions in adrenal
glands (Kapusta, 1995). Thus, peripherally restricted opioids
should be devoid of the CNS side effects, and produce fewer
or less severe adverse actions having both CNS and peripheral
components such as constipation, nausea, vomiting (µ-opioids),
and diuresis (κ-opioids). Some authors suggested that peripheral
µ-receptors mediate morphine-induced analgesic tolerance and
paradoxical hyperalgesia, but not analgesia itself, using mice with
µ-receptor deletion in TRPV1-expressing neurons (Corder et al.,
2017). This is in contrast to studies in mice with µ-receptor
deletion in Nav1.8-expressing neurons, which showed that
peripheralµ-receptors do not contribute to analgesic tolerance or
hyperalgesia induced by morphine or its metabolite (Weibel et al.,
2013; Roeckel et al., 2017). Further work will be required to find
out whether these contradictory findings are related to different
µ-receptor-expressing neuronal populations or unidentified
knockout strategy-related alterations. Nevertheless, in agreement
with the latter studies, experiments without genetic modifications
showed that development of tolerance at peripheral µ-receptors
is reduced in inflamed tissue in animals and humans, due to the
continuous presence of immune cell-derived opioid peptides and
enhanced µ-receptor recycling (Stein et al., 1996; Zöllner et al.,
2008).
Additional advantage of peripheral opioid receptor targeting is
the inhibition of pain at its source, since many painful syndromes
originate in peripheral tissue and are usually associated with
inflammation (including surgery, arthritis, neuropathy, cancer,
and visceral disorders). Under such conditions, opioid receptor
synthesis, transport, and G protein coupling in peripheral sensory
neurons is increased, and disruption of the perineurial barrier
facilitates the access of opioids to receptors (Hassan et al.,
1993; Antonijevic et al., 1995; Zöllner et al., 2003; Hackel et al.,
2012; Mousa et al., 2007, 2017). Moreover, damaged tissue
is infiltrated by immune cells containing opioid peptides and
expressing functional opioid receptors (Stein et al., 1990, 1993,
1996; Rittner et al., 2001; Labuz et al., 2009; Boué et al., 2014;
Celik et al., 2016). All these events lead to enhanced analgesic
efficacy of opioids at peripheral receptors. This has been shown
Frontiers in Pharmacology | www.frontiersin.org 3 November 2018 | Volume 9 | Article 1388
fphar-09-01388 November 28, 2018 Time: 17:7 # 4
Machelska and Celik New Opioids, Analgesia, Side Effects
FIGURE 2 | Mechanisms of opioid-induced side effects. (A) G protein-mediated side effects in response to activation of opioid receptors (OR). (1) Respiratory
depression: Gβγ-dependent activation of GIRK channels. (1 and 2) Sedation and constipation: Gβγ-dependent activation of GIRK channels (1) and inhibition of Cav
channels (2). (3) Nausea and vomiting: Gαi/o-mediated inhibition of AC, decreased cAMP levels and PKA activity, and inhibition of Cav channels; this is based on
indirect evidence (indicated by a question mark). (4 and 5) Analgesic tolerance, reward/euphoria, dependence/withdrawal, or aversion/dysphoria: Gβγ-mediated AC
activation, elevated cAMP levels, enhanced PKA activity, and activation of Nav channels (4). Phosphorylation of OR by various kinases (5), including PKA and
activated by Gβγ PKC, CaMK II, and MAPK, which results in OR uncoupling form G protein-mediated effects. (B) β-arrestin-dependent actions. After even brief
activation by an opioid, OR are phosphorylated by GRK recruited by Gβγ, followed by β-arrestin binding to phosphorylated OR (1), which terminates G protein
coupling and signaling (2), and leads to OR internalization (3). Dephosphorylated OR can be recycled to the cell membrane (4) or directed to lysosomes and
degraded (5). β-arrestin-2 might also promote morphine-induced respiratory depression, constipation, analgesic tolerance, and κ-receptor-mediated aversion, and
dampen morphine-induced reward. Some of these effects may involve MAPK activation (6), but mechanisms are unknown (indicated by question marks).
following local application of small, systemically inactive doses
of opioids in animal models and in humans (Kalso et al., 2002;
Stein et al., 2003; Zeng et al., 2013; Stein, 2016). Importantly,
pharmacologic, genetic, and clinical studies have demonstrated
that peripheral opioid receptors mediate a large proportion of the
analgesic effects produced by systemically administered opioids
(Gavériaux-Ruff, 2013; Jagla et al., 2014; Stein and Jagla, 2014;
Stein, 2016).
Reducing Opioid Access to the CNS
The above described findings stimulated the development of
peripherally restricted opioid receptor agonists by limiting their
ability to cross the blood-brain barrier (BBB) (Figure 4A).
These strategies focused on κ-opioids, supported by a recent
study (Snyder et al., 2018), and include agonist chemical
modifications (e.g., incorporation of quaternary structures
or amphiphilic molecules which contain hydrophilic and
hydrophobic components), and synthesis of peptide-based
compounds. However, these modifications often decreased
agonist affinity to receptors, which required the use of
relatively high doses and did not warrant complete BBB
impermeability (Barber and Gottschlich, 1997; Rivière, 2004;
Stein and Machelska, 2011). This also applies to peptides, as
in contrast to previous beliefs, peptides can cross the BBB
(Kastin and Pan, 2010). Nevertheless, two κ-receptor agonists
gained pharmaceutical interests, asimadoline (initially termed
EMD 61753) and CR845 (formerly FE 202845) (Figure 4A and
Table 1). Asimadoline belongs to the amphiphilic molecules and
possesses somewhat puzzling action profile. In animal models of
hind paw inflammation or sciatic nerve injury, it alleviated pain
(Barber et al., 1994) or produced bi-phasic effects, with analgesia
at lower doses or shortly after injection, but paradoxically
increased pain at higher doses or at later time points (Machelska
et al., 1999; Walker et al., 1999). As the analgesic actions were
mediated by peripheral κ-receptors, the hyperalgesic effects were
either κ-receptor-selective (Walker et al., 1999) or independent
of κ- and N-methyl-D-aspartic acid receptors (Machelska et al.,
1999). Asimadoline was also hyperalgesic in experimental colonic
distension model in healthy human volunteers (Delgado-Aros
et al., 2003) and tended to enhance postoperative pain in patients
undergoing arthroscopic knee surgery (Machelska et al., 1999).
In contrast, in preclinical models of visceral inflammatory pain
(Gebhart et al., 2000), barostat-induced colonic distension in
patients with irritable bowel syndrome (IBS) (Delvaux et al.,
2004), and in phase 2b IBS trial (Mangel et al., 2008; Mangel
and Williams, 2010), asimadoline was reported to decrease
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FIGURE 3 | Representation of body structures involved in opioid-induced analgesia (A) and side effects (B).
pain. It produced some side effects, which could be of CNS
(sedation, headache, dizziness) or both CNS and peripheral origin
(diuresis), albeit at higher than analgesic doses (Mangel and
Hicks, 2012). These results led to the conclusion that in contrast
to somatic pain, asimadoline may be efficacious in the visceral
pain, and it is now developed for management of diarrhea-
predominant IBS with moderate-to-severe pain (Mangel and
Hicks, 2012; Foxx-Orenstein, 2016).
CR845 is a tetrapeptide currently under development by Cara
Therapeutics (Stamford, CT, United States) for postoperative
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FIGURE 4 | Strategies for safer pain control – targeting opioid receptors. (A) Targeting opioid receptors (OR) in peripheral painful tissue by chemical modification of
agonists, which results in their decreased blood-brain barrier penetration (1), nanocarrier-based opioid delivery to inflamed tissue (2), or by low pH-dependent OR
activation (3). (B) Biased agonism: This approach aims at targeting OR–G protein signaling without activation of β-arrestins, which were considered to mediate
opioid-induced side effects, but not analgesia. This might need reconsideration, since G proteins not only mediate analgesia but also side effects (see also
Figure 2A). (C) Targeting heteromers. (D) Development of multifunctional ligands, which act as µ- and δ-opioid receptor agonists and NK1 receptor antagonists, or
µ- and NOP-receptor agonists. (E) Targeting truncated, 6TM domain µ-receptor variants. Question marks indicate that heteromer/multiple receptor selectivity of the
ligand was not tested or not confirmed (see also Tables 2, 3).
and osteoarthritis pain. Its analgesic effects were reported in
animal models of pancreatitis, abdominal, inflammatory, and
neuropathic pain. Completed phase 2 clinical trials stated
that CR845 attenuated postoperative pain after laparoscopic
hysterectomy and in some patients after bunionectomy, and
it was well tolerated with repetitive dosing over 2 weeks
in patients with osteoarthritis of knee or hip. The side
effects were considered mild and, similar to asimadoline, they
included dizziness, headache, and diuresis. However, these data
were only presented in abstracts, press releases, and at the
ClinicalTrials.gov website (Albert-Vartanian et al., 2016), and
thus, independent, peer-reviewed studies will be essential to
verify these findings.
Nanocarrier-Based Approaches
A promising strategy to alter the pharmacokinetic profile and
improve therapeutic effects of drugs is the use of nanoparticles as
drug carriers. Nanoparticles are defined as molecules of 1–100 nm
in at least one dimension, and examples include liposomes,
micelles, and polymer-based particles. They have been widely
examined for tumor-directed delivery of chemotherapeutics to
reduce their off-target toxicity (Cheng et al., 2012). Similar
strategies have recently been used to deliver opioids to peripheral
inflamed tissue (Figure 4A). Liposomes conjugated with an
antibody to intercellular adhesion molecule-1 (anti-ICAM-1)
were employed to mimic the properties of immune cells (Hua
and Cabot, 2013). Indeed, it has earlier been shown that similar
to selectins and integrins α4 and β2 (Machelska et al., 1998,
2004), ICAM-1 expressed on vascular endothelium mediates
the migration of opioid peptide-containing immune cells to
peripheral inflamed tissue to locally alleviate pain (Machelska
et al., 2002). Accordingly, intravenously injected anti-ICAM-1-
conjugated liposomes loaded with µ-receptor agonist loperamide
accumulated in inflamed tissue and alleviated mechanical
hypersensitivity via local opioid receptors in a rat model of
unilateral hind paw inflammation (Hua and Cabot, 2013). In
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TABLE 1 | Novel opioid treatments in clinical trials.






Postoperative pain (knee surgery); randomized,
double-blind, placebo-controlled; oral
- Tendency to hyperalgesia
- No serious side effects (data not shown)
a




- Side effects comparable to placebo (dizziness,
nausea, headache)
b
IBS (barostat-induced colonic distension);
randomized, double-blind, placebo-controlled; oral
- Analgesia
- Side effects not reported
c
IBS; randomized, double-blind, placebo-controlled;
oral
- Analgesia in D-IBS




Postoperative pain (hysterectomy, bunionectomy);
oral, i.v.
- Analgesia
- Side effects: dizziness, headache, diuresis
e
Biased agonists Oliceridine (TRV130)
(µ-receptors)
Healthy volunteers (cold pain test); randomized,
double-blind, placebo-controlled; i.v.
- Analgesia (superior to morphine)
- Side effects: vs. morphine, lesser nausea, similar
respiratory depression
f
Postoperative pain (bunionectomy); randomized,
double-blind, placebo-controlled; i.v.
- Analgesia (superior to morphine)
- Side effects: constipation, nausea,
vomiting, dizziness similar to morphine
g
Postoperative pain (abdominoplasty); randomized,
double-blind, placebo-controlled; i.v. PCA
- Analgesia (similar to morphine)
- Side effects: lesser nausea and vomiting vs.
morphine
h
Nalfurafine (κ-receptors) Approved for uremic pruritus in Japan, but not in
Europe
Sedation in analgesic doses (not recommended for
pain treatment)
i
DENK inhibitors PL37, PL265
(enkephalin peptidases)
Postoperative pain (PL37), neuropathic and ocular
pain (PL265)
Data not available j, k
Gene therapy HSV-PENK (enkephalin
overexpression in DRG
neurons)
Intractable cancer pain; not randomized, not
blinded, not placebo-controlled; intradermal
- Analgesia vs. pre-injection
- Side effects: transient and mild injection site
erythema and pruritus, body temperature elevation
l
Intractable cancer pain; randomized, double-blind,
placebo-controlled; intradermal





Osteoarthritis and low back pain; randomized,
double-blind, placebo-controlled; oral
Data not available n
D-IBS, diarrhea-predominant irritable bowel syndrome; I.v., intravenous; PCA, patient-controlled analgesia. ∗Currently under development for D-IBS with moderate-to-
severe pain. Sedation, headache, dizziness, diuresis – in higher than D-IBS analgesic dose (Mangel et al., 2008; Mangel and Williams, 2010; Foxx-Orenstein, 2016).
#Currently under development for postoperative and osteoarthritis pain. Data in abstracts, press releases, ClinicalTrials.gov; No published peer-reviewed trials. (a)
Machelska et al., 1999; (b) Delgado-Aros et al., 2003; (c) Delvaux et al., 2004; (d) Mangel et al., 2008; (e) Albert-Vartanian et al., 2016; (f) Soergel et al., 2014; (g)
Viscusi et al., 2016; (h) Singla et al., 2017; (i) Inui, 2012; (j) Roques et al., 2012; (k) http://www.pharmaleads.com; (l) Fink et al., 2011; (m) ClinicalTrials.gov NCT01291901;
(n) ClinicalTrials.gov NCT02367820 and NCT02362672.
the same model, analgesic effects were exerted by loperamide-
encapsulated liposomal gel applied topically on the inflamed paw
(Iwaszkiewicz and Hua, 2014). In both cases, anti-inflammatory
effects were also observed, and all actions of loperamide-loaded
liposomes were superior to either conventional loperamide or
loperamide gel, respectively. However, in the rat model of
polyarthritis, despite producing analgesia, loperamide liposomal
gel unexpectedly exacerbated arthritis (Table 2). As the opioid
receptor-selectivity has not been tested, the mechanisms of these
actions are currently unclear (Hua et al., 2017).
Another nanocarrier-based approach utilized hyperbranched,
dendritic polyglycerols (PG) to deliver morphine to peripheral
inflamed tissue. Morphine was covalently bound to PG via
cleavable ester linker sensitive to esterases and low pH (González-
Rodríguez et al., 2017). The rationale was that due to its
high molecular weight and hydrophilicity, such PG-morphine
injected intravenously will not cross the BBB, but will selectively
extravasate from leaky blood vessels characteristic of inflamed
tissue. The local low pH and leukocyte esterases will then trigger
the release of morphine from PG-morphine to ameliorate pain
(Fleige et al., 2012; Nehoff et al., 2014). Indeed, in contrast
to morphine, intravenous PG-morphine exclusively produced
analgesia via peripheral opioid receptors in painful tissue without
sedation and constipation, in a rat model of unilateral hind
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TABLE 2 | Novel opioid treatments in preclinical models of pathological pain.







- CFA hind paw inflammation
- Paw pressure test
- I.v. or gel on inflamed paw
- Blinding (+), R (+), SSE (−)
- Analgesia
- Decreased paw volume
- Side effects not evaluated
a, b
- CFA polyarthritis
- Paw pressure test
- Gel on inflamed paws
- Blinding (+), R (+), SSE (−)
- Analgesia






- CFA hind paw inflammation
- Paw pressure test
- Into inflamed paw, i.v.
- Blinding (+), R (+), SSE (−)
- Analgesia







- CFA hind paw inflammation
- Hind paw incision
- CCI neuropathy
- Paw pressure, von Frey, Hargreaves tests
- Into inflamed paw, i.v., s.c.
- Blinding (+), R (−), SSE (+)
- Analgesia
- No sedation, constipation, motor impairment,
reward (CPP), respiratory depression (naïve




- CFA hind paw inflammation
- Hind paw incision
- CCI neuropathy
- Paw pressure, von Frey, Hargreaves tests
- I.v., s.c.
- Blinding (+), R (−), SSE (+)
- Analgesia
- Sedation, constipation, motor impairment,
reward (CPP), respiratory depression (naïve







- Lipopolysaccharide (LPS) systemic
inflammation
- CFA hind paw inflammation
- Bone cancer
- SNI neuropathy
- Tail-flick, von Frey tests
- Supraspinal, spinal
- Blinding (−,+)∗, R (−), SSE (−)
- Analgesia; µ–mGluR5 selectivity not confirmed
- No analgesic tolerance, no respiratory
depression after spinal injection (LPS or naïve






- von Frey test
- Intraperitoneal
- Blinding (+), R (+), SSE (−)
- Analgesia; µ–CCR5 selectivity not tested







TY027 (CNS µ-, δ-, and
NK1 receptors)
- SNL neuropathy
- Paw pressure, von Frey, Hargreaves tests
- Supraspinal, spinal, i.v.
- Blinding (only ferrets), R (only ferrets), SSE
(−)
- Analgesia
- No constipation, reward (CPP), analgesic
tolerance, withdrawal (teeth chattering,
wet-dog shakes, diarrhea, weight loss) (naïve




µ-, δ-, and NK1 receptors)
- CCI neuropathy
- von Frey, cold plate tests
- Spinal
- Blinding (−), R (−), SSE (−)
- Analgesia






- CFA hind paw inflammation
- Zymosan ankle inflammation
- SNI neuropathy
- von Frey test, facial grimacing; S.c.
- Blinding (−,+)∗, R (+), SSE (−)
- Analgesia
- Less constipation, no reward (CPP),
respiratory depression, withdrawal (jumping);
analgesic or 2.5-fold higher doses
m, n
(Continued)
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- von Frey, Hargreaves tests
- Into ipsilateral paw
- Blinding (+), R (+), SSE (−)
- Reduced basal von Frey sensitivity
- Enhanced morphine
- and loperamide-analgesia




Analog 4 (ZH853) (CNS
µ-receptors)
- CFA hind paw inflammation
- Hind paw incision
- SNI neuropathy
- Paw pressure, von Frey, Hargreaves tests
- Oral, spinal, i.v., s.c.
- Blinding (+), R (−,+)∗, SSE (−)
- Analgesia
- Less analgesic tolerance, motor impairment,
reward (CPP, SA), respiratory depression (naïve
mice or rats); 2-fold lower or analgesic doses
p, q
CCI, chronic constriction injury; CFA, complete Freund’s adjuvant; I.v., intravenous; R, randomization; SA, self-administration; S.c., subcutaneous; SNI, spared nerve
injury; SNL, spinal nerve ligation; SSE, sample size estimation; TM, transmembrane domain. ∗Each sign refers to the corresponding reference (in the citation order).
Marked in bold are compounds currently the most comprehensively examined (pathological pain models, various side effects) and showing promising results. (a) Hua and
Cabot, 2013; (b) Iwaszkiewicz and Hua, 2014; (c) Hua et al., 2017; (d) González-Rodríguez et al., 2017; (e) Spahn et al., 2017; (f) Rodriguez-Gaztelumendi et al., 2018;
(g) Spahn et al., 2018; (h) Akgün et al., 2013; (i) Peterson et al., 2017; (j) Cataldo et al., 2018; (k) Largent-Milnes et al., 2013; (l) Starnowska et al., 2017; (m) Majumdar
et al., 2011; (n) Wieskopf et al., 2014; (o) Klein et al., 2018; (p) Zadina et al., 2016; (q) Feehan et al., 2017.
paw inflammation (Table 2). Consistent with these actions,
free morphine was only measured in inflamed paw tissue, but
not in the contralateral, non-inflamed paw tissue, blood, and
brain (González-Rodríguez et al., 2017). Together, although
polyglycerols are biocompatible (Kainthan et al., 2006), the
organ toxicity and broader side effect profile, including abuse
potential and effects on respiration of PG-morphine need to
be investigated to strengthen the clinical applicability of this
strategy.
Painful Tissue-Specific Opioid Receptor
Activation
Recent studies explored the opioid receptor–ligand interactions
that are specific to pathological painful conditions such as
acidosis (pH 5–7 vs. 7.4 in non-inflamed tissue) (Spahn et al.,
2017). An agonist designed to fulfill such requirements could
freely distribute throughout the whole body, including the
brain, but would only activate opioid receptors in peripheral
inflamed tissue (Del Vecchio et al., 2017) (Figure 4A). This has
been achieved by lowering the dissociation constant (pKa) of
the µ-receptor agonist fentanyl to the acidic pH. Accordingly,
fluorination of fentanyl (pKa 8.43) by computer simulations
resulted in a design of a novel compound NFEPP [(±)-N-
(3-fluoro-1-phenethylpiperidine-4-yl)-N-phenyl propionamide]
with a pKa 6.8, which can only be protonated, and thus
bind to receptors, at lower than physiological pH. Indeed,
in vitro experiments confirmed that NFEPP bound to and
activated µ-receptors only at acidic pH, whereas fentanyl was
active at both acidic and physiological pH. Importantly, unlike
fentanyl, intravenously applied NFEPP produced analgesia by
activation of opioid receptors exclusively in peripheral injured
tissue in rat models of unilateral hind paw inflammation or
surgical incision (Spahn et al., 2017), sciatic nerve injury-induced
neuropathy, and abdominal pain (Rodriguez-Gaztelumendi
et al., 2018). Furthermore, NFEPP did not induce respiratory
depression, sedation, motor impairment, reward (assessed by
conditioned place preference; CPP), and constipation, even at
doses 10-fold higher than the most effective analgesic doses
(Spahn et al., 2017) (Table 2). As this compound will not be
an option for patients with CNS inflammation, it represents
a promising analgesic for pain conditions associated with
peripheral tissue damage, which needs to be demonstrated in
clinical trials.
Interestingly, another fentanyl derivative FF3 ((±)-N-[1-(2-
fluoro-2-phenylethyl)piperidine-4-yl]-N-phenyl propionamide)
with a higher than NFEPP’s pKa, 7.22 (but still lower than
that of fentanyl), produced injury-restricted analgesia in rat
models of inflammatory, surgical, neuropathic, and abdominal
pain, similarly to NFEPP. However, unlike NFEPP, FF3
induced side effects, including respiratory depression, sedation,
motor impairment, reward, and constipation, at 2.5–10-fold
higher than analgesic doses (Table 2). These results suggest
that a ligand’s pKa should be close to the pH of injured




The concept of biased agonism (or functional selectivity) is
based on the ability of different ligands of the same receptor
to stabilize various receptor active states, which leads to the
activation of diverse signaling pathways – a biased agonist
preferentially activates one signaling pathway over another.
Some biased agonists of GPCRs, including opioid receptors,
might activate G protein-mediated pathway, whereas others
might involve β-arrestin-2. The role of β-arrestin-2 was first
examined in the µ-receptor function using β-arrestin-2 knockout
mice. These studies used naïve mice, without pathological
pain, and reported that morphine induced more efficacious
and prolonged analgesia in acute heat pain tests, absent
(in hot plate test) or delayed (in tail-flick test) analgesic
tolerance, and decreased constipation and respiratory depression
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in β-arrestin-2 knockout compared to wild-type mice (Bohn
et al., 1999, 2000, 2002; Raehal et al., 2005). Whereas
naloxone-precipitated morphine withdrawal was unchanged
(Bohn et al., 2000), morphine-induced hypothermia and reward
(CPP) were substantially enhanced in β-arrestin-2 knockout mice
(Bohn et al., 1999, 2003) (Figure 2B). Of note, analgesic tolerance
and naloxone-precipitated withdrawal following injection of
other µ-receptor agonists such as fentanyl, oxycodone, and
methadone did not differ between β-arrestin-2 knockout and
wild-type mice (Raehal and Bohn, 2011). Intriguingly, opposite
effects were observed using GRK3 knockout mice, who showed
weaker acute analgesic tolerance to fentanyl, oxycodone, and
methadone, but not to morphine (Melief et al., 2010). Further
work of that group indicated that analgesic tolerance to fentanyl
involves GRK3/arrestin and c-Jun N-terminal kinase-2 belonging
to the MAPK family, whereas tolerance to morphine also
involves this kinase, but in GRK3/arrestin-independent manner
(Kuhar et al., 2015). It is unclear whether these contradictory
results relate to different actions mediated by GRK3 and
β-arrestin-2 in response to µ-receptor activation, or to other,
unknown alterations resulting from knockout strategies, which
cannot be excluded, since GRKs and β-arrestins interact with
many GPCRs, not only with opioid receptors (Reiter et al.,
2012). Regardless of the discrepancies, these findings suggest
that GRK3 and β-arrestin-2 are not essential for side effects
exerted by µ-agonists, and that β-arrestin-2 might actually be
required for dampening the reinforcement/abuse potential of
morphine. Nevertheless, the following efforts focused on design
of agonists without or with minimal β-arrestin-2 recruitment
properties, but with bias toward G protein-mediated signaling
(Figure 4B).
It is currently accepted that biased agonism occurs at
all three opioid receptors (Al-Hasani and Bruchas, 2011;
Siuda et al., 2017). There is in vitro evidence that δ-receptors
can adopt distinct receptor conformations in response to
different agonists, and that agonist-dependent δ-receptor
trafficking and different arrestin isoform recruitment may have
behavioral implications (Vicente-Sanchez and Pradhan, 2017).
However, no biased δ-receptor agonists with a potential
distinction between analgesic actions and undesirable
effects such as convulsions have been developed so far.
Therefore, the following sections focus on µ- and κ-opioid
receptors.
µ-Receptor Biased Ligands
The first G protein-biased µ-receptor agonist was oliceridine
(formerly TRV130) (DeWire et al., 2013) and initially it was
classified as potent analgesic with reduced side effect profile
(Kingwell, 2015). However, closer analysis of the data and
subsequent studies appear less consistent. In mice, oliceridine
produced similarly effective analgesia in acute heat pain test,
but less constipation compared to morphine. Both agonists also
exerted comparable analgesia in a short-lasting (24 h) post-
operative pain model in rats. Respiratory function was not
affected by either opioid at the most effective analgesic doses,
but it was to a similar degree diminished by approximately 2.5-
fold (oliceridine) or 4-fold (morphine) higher doses in naïve rats
(DeWire et al., 2013). Subsequent study in rodents confirmed
oliceridine-induced analgesia and lack of analgesic tolerance in
acute heat pain test, but also reported robust constipation and
abuse-related behavior in intracranial self-stimulation (ICSS)
assay (Altarifi et al., 2017) (Table 3). In healthy human
volunteers, compared to morphine, oliceridine exerted superior
analgesia in experimental cold pain test, less severe nausea, and
comparable degree, but shorter-lasting respiratory depression,
which paralleled the time-course of its analgesic effect (Soergel
et al., 2014). In phase 2 trial examining patients undergoing
bunionectomy, oliceridine produced greater post-operative pain
relief, but similar to morphine side effects characterized by
the percentage of patients experiencing constipation, nausea,
vomiting, and dizziness, as well as by the severity and
number of these events (Viscusi et al., 2016). The most
recent phase 2b study in patients undergoing abdominoplasty
reported comparable rescue analgesic use and reduction in
pain intensity, but significantly lower percentage of patients
experiencing nausea and vomiting following oliceridine vs.
morphine treatment. Whereas earlier clinical trials used fixed-
dose design, in that latest study opioids were delivered on
an as-needed basis via patient-controlled analgesia (Singla
et al., 2017) (Table 1). Together, as all so far performed
pre-clinical and clinical studies consistently showed analgesia
induced by oliceridine, its side effect profile appears more
variable across the studies with most reporting comparable
to morphine adverse actions. Additional limitation is the
abuse liability of oliceridine (Altarifi et al., 2017) and possibly
of other G protein-biased µ-receptor agonists (Bohn et al.,
2003).
G protein-biased ligands with µ-receptor agonistic activity,
but also affinities to other opioid receptors were later described.
PZM21 was initially characterized as µ-receptor agonist with
κ-receptor antagonistic activity, and no β-arrestin-2 recruitment.
It was reported to produce analgesia in acute heat pain test
and in short-lasting (30 min) hind paw inflammation in
mice, but no respiratory depression and rewarding (CPP)
properties, and less constipation than morphine. However,
the side effects were examined in equivalent or lower than
the most effective analgesic doses (Manglik et al., 2016).
Furthermore, in contrast to that report, a recent study re-
examining PZM21 found that it induced respiratory depression
similarly to morphine. Additionally, following repeated
administration, tolerance developed to PZM21-induced
analgesia but not to respiratory depression (Hill et al., 2018)
(Table 3).
Mitragynine pseudoindoxyl is a derivative of the natural
product mitragynine, which in vitro preferentially activated
G protein without β-arrestin-2 recruitment, and acted as
µ-receptor agonist as well as δ- and κ-receptor antagonist.
In vivo it produced µ-receptor-mediated analgesia in acute
heat pain test, delayed analgesic tolerance, lesser constipation,
naloxone-precipitated withdrawal and respiratory depression,
and no reward compared to morphine or aversion compared
to the κ-receptor agonist U50,488H (CPP/conditioned place
aversion; CPA). The doses of mitragynine pseudoindoxyl used
to examine side effects were higher than ED50, but still
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TABLE 3 | Novel opioids tested in animals without pathological pain.
Category Name/Receptor selectivity Experimental conditions∗ Effects# Reference
Biased ligands Oliceridine (TRV130) (µ-agonist) - Tail-flick; S.c.
- Blinding (−), R (+), SSE (−)
- Analgesia
- No analgesic tolerance




- Tail-flick, hot plate
- Hind paw inflammation (30 min); S.c.
- Blinding (only hot plate), R (−),
SSE (−)
- Analgesia (not in tail-flick)
- Less constipation, no respiratory depression,
reward (CPP)
b
- Hot plate; S.c., i.p.
- Blinding (+), R (+), SSE (+)
- Analgesia
- Respiratory depression
- Tolerance to analgesia, but not to respiratory







- S.c., oral, supraspinal
- Blinding (−), R (−), SSE (−)
- Analgesia
- Less constipation, withdrawal (jumping),
respiratory depression, no reward, aversion
(CPP/CPA)
d
RB-64 (κ-agonist) - Hot plate; S.c.
- Blinding (−), R (−), SSE (−)
- Analgesia
- No sedation, motor impairment,
aversion/anhedonia in ICSS
- Robust aversion in CPA
e
Triazole 1.1 (κ-agonist) - Tail-flick; S.c., i.p.
- Blinding (−), R (−), SSE (+)
- Analgesia
- No sedation, aversion (ICSS)
f
Heteromer ligands CYM51010 (µ–δ heteromer
agonist)
- Tail-flick
- S.c., i.p., spinal
- Blinding (−), R (−), SSE (−)
- Analgesia (partially reversed by µ–δ-specific
antibody)
- Less analgesic tolerance, diarrhea, body weight








- Blinding (−), R (−), SSE (−)
- Analgesia (µ–δ selectivity not tested)
- No analgesic tolerance, withdrawal (jumping),
reward (CPP)
h,i
NNTA (monovalent agonist of
putative µ–κ heteromers)
- Tail-flick
- I.v., supraspinal, spinal
- Blinding (−), R (−), SSE (−)
- Analgesia (µ–κ selectivity not tested)
- No analgesic tolerance, withdrawal (jumping),
reward (CPP)
- Strong aversion (CPA)
j
INTA (monovalent agonist of
putative µ–κ and/or δ–κ
heteromers)
- Tail-flick
- S.c., supraspinal, spinal
- Blinding (−), R (−), SSE (−)
- Analgesia (µ–κ or δ–κ selectivity not tested)
- No analgesic tolerance, aversion (CPA)




AT-121 (µ- and NOP-agonist) - Rhesus monkeys
- Naïve and capsaicin
- Tail immersion
- S.c.
- Blinding (+), R (−), SSE (−)
- Analgesia (µ- and NOP-selective)
- No analgesic tolerance, scratching, reward (SA),
respiratory depression, withdrawal (increased
respiration, heart rate, arterial pressure); up to




NKTR-181 (µ-agonist) - Hot plate
- Writhing test
- Oral
- Blinding, R (+; but not for SA and
rigidity), SSE (−)
- Analgesia; receptor selectivity and action site not
tested
- No reward (SA), mild muscle rigidity and motor
impairment at the most effective analgesic doses
m
I.p., intraperitoneal; I.v., intravenous; R, randomization; SA, self-administration; S.c., subcutaneous; SSE, sample size estimation. ∗Experiments were performed in mice or
rats, unless otherwise stated. #Side effects were tested in analgesic or lower doses, unless otherwise stated. (a) Altarifi et al., 2017; (b) Manglik et al., 2016; (c) Hill et al.,
2018; (d) Váradi et al., 2016; (e) White et al., 2015; (f) Brust et al., 2016; (g) Gomes et al., 2013; (h) Daniels et al., 2005; (i) Lenard et al., 2007; (j) Yekkirala et al., 2011; (k)
Le Naour et al., 2014; (l) Ding et al., 2018; (m) Miyazaki et al., 2017.
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substantially lower than the most effective analgesic doses
(Table 3). Additionally, the relative contribution of its µ-receptor
agonist/δ- and κ-receptor antagonist activity and G protein bias
to the improved side effect profile is unclear (Váradi et al.,
2016).
A recent paper suggested that just the occurrence of biased
signaling might be insufficient, and the degree of bias or
bias factor (which quantitatively defines the preference for
one signaling pathway over another) closer predicts the opioid
therapeutic window (i.e., the separation of doses that produce
analgesia and doses that produce side effects). Thus, the
higher the G protein bias factor the better the therapeutic
window, as calculated for several µ-receptor agonists by
comparing respiratory depression and analgesia. Generally,
the authors found a correlation between the bias factor and
therapeutic window. Nevertheless, it is difficult to clearly
define the best bias factor, since it strongly depended and
substantially varied with the in vitro assays and conditions
(e.g., cell line, native tissue, mouse vs. human µ-receptors,
signaling pathway type). Similarly, the therapeutic window varied
with the pain tests (tail-flick or hot plate) and respiratory
depression parameters (arterial oxygen saturation or breath
rate). For example, for the most G protein-biased compound
SR17018, the G protein bias factor varied from 40 to 102
and therapeutic window for respiratory depression vs. analgesia
ranged from 26 to 105 (Schmid et al., 2017); the bias factor
of 3 was calculated for oliceridine (DeWire et al., 2013).
Furthermore, the correlation between the bias factor and
therapeutic window in pathological pain models and for other
opioid side effects (constipation, reward, physical dependence) is
unknown.
κ-Receptor Biased Ligands
Nalfurafine (previously TRK-820), first synthetized and
characterized in the late 1990s, is a κ-receptor agonist with
particularly strong G protein bias at human κ-receptors (bias
factor of 300 vs. 7 for rat κ-receptors) (Schattauer et al., 2017).
It was initially described as efficacious analgesic and antipruritic
with favorable side effect profile; however, a recent study
demonstrated its aversive/anhedonic effects (in ICSS assay) in
rats (Lazenka et al., 2018). Furthermore, it produced severe
sedation at analgesic doses in humans, but lower doses decreased
pruritus without severe side effects. Nalfurafine is currently used
in Japan for the treatment of uremic pruritus in individuals
undergoing hemodialysis (Inui, 2012), but was not approved in
Europe, and it is not recommended for the treatment of pain
(Inui, 2012)1 (Table 1).
RB-64 is a derivative of salvinorin A, an active
psychotropic ingredient of a plant Salvia divinorum, with
a G protein/β-arrestin-2 bias factor of 96 (vs. 3 for typical
κ-agonist U69593) (White et al., 2015). It produced κ-receptor-
selective analgesia in acute heat pain test, but did not induce
sedation, motor impairment, and aversion/anhedonia in ICSS
assay compared to U69593 and salvinorin A; however, it was
1https://www.ema.europa.eu/documents/medicine-qa/withdrawal-marketing-
authorisation-application-winfuran-nalfurafine_en.pdf
aversive in the CPA paradigm (Table 3). Additionally, U69593
and salvinorin A produced similar analgesia, sedation, and
aversion in wild-type and β-arrestin-2 knockout mice, and
only motor impairment was slightly lesser in the latter. These
data suggest that analgesia and most side effects induced by
κ-opioids are mediated by G protein-, but not by β-arrestin-
2-dependent signaling. Thus, although RB-64 did not recruit
β-arrestin-2 in vitro (White et al., 2015), it is unclear whether
the lack of β-arrestin-2 signaling indeed account for its effects
in vivo.
Another G protein-biased κ-receptor agonist triazole 1.1
(with G protein/β-arrestin-2 bias factor of 28) produced
similar degree analgesia in acute heat pain test and an anti-
pruritic activity, but did not decrease dopamine release
in the striatum and did not possess sedative and aversive
properties (in ICSS test) compared to classic κ-receptor
agonist U50,488H (Brust et al., 2016). Still, the fact that
triazole 1.1 was not tested in chronic pathological pain
models and the analgesic doses from acute pain tests
were used to examine side effects pose some limitations
(Table 3).
In summary, the idea to separate desirable and undesirable
opioid actions by biased agonists stimulated pain research in
the last decades. As analgesic effects of µ- and κ-receptor
biased agonists were examined in animals without pain or in
very short-lasting inflammation (30 min–24 h) (Table 3), it
will be essential to use animal models of pathological pain
to closer reflect clinical conditions. To broaden therapeutic
window, it is desirable to also use doses exceeding the most
effective analgesic doses for testing adverse actions, since fatal
effects result from overdosing, as in case of respiratory arrest.
The potential abuse liability of G protein-biased µ-receptor
agonists, as in case of oliceridine, even in the absence of other
side effects, must be seriously considered. Clearly, the addictive
properties of opioids have led to their misuse and abuse, which
resulted in the opioid crisis worldwide (Abdel-Hamid et al.,
2016; Novak et al., 2016; Volkow et al., 2018). Although bias
factor depends on experimental conditions and cannot be used
as an absolute predictor of the ligand action, the degree of bias
is often emphasized, but even very high bias factor does not
guarantee the absence of side effects, as in case of nalfurafine.
Moreover, it was not always clear whether in vivo actions of
biased agonists indeed resulted from G protein bias and the lack
of β-arrestin-2 engagement, or from a complex pharmacological
profile or yet unidentified pathways, as in case of mitragynine
pseudoindoxyl and RB-64. Considering these issues, including
uncertain mechanistic basis for action of biased agonists, it
needs to be acknowledged that opioid-mediated side effects do




Heteromers are defined as complexes composed of at least
two functional receptor units (protomers) and having different
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biochemical properties than the individual units. Additional
criteria include the colocalization and physical interaction
of protomers, and the ability to alter heteromer action by
heteromer-specific reagents (Gomes et al., 2016). Heteromers
might thus potentially exhibit new pharmacology and represent
a novel therapeutic target (Figure 4C). In vitro studies in
heterologous cells indicated heteromerization between
opioid receptors to form µ–δ, µ–κ, and δ–κ heteromers,
as well as between opioid and other receptors to form
heteromers such as µ-opioid–gastrin-releasing peptide receptor,
µ-opioid–metabotropic glutamate receptor 5 (mGluR5),
µ-opioid–chemokine receptor 5 (CCR5), µ-opioid–neurokinin
1 (NK1) receptor, µ-opioid–cannabinoid 1, and δ-opioid–
cannabinoid 1 receptor. There is only scarce evidence that such
complexes exist in endogenous systems, and onlyµ–δ heteromers
appear to fulfill the criteria required for heteromerization in
native tissue (Gomes et al., 2016). For example, using µ–δ
heteromer-specific antibody, this heteromer was detected
in cultured DRG neurons and in various pain-related brain
areas in mice (Gupta et al., 2010), although some authors
question the co-expression of µ- and δ-receptors in DRG
neurons (Wang et al., 2018). Screening of a small molecule
library identified CYM51010 as the µ–δ heteromer agonist.
This compound produced analgesia in acute heat pain test,
which was partially reversed by µ–δ heteromer antibody.
Compared to morphine, CYM51010 induced lesser analgesic
tolerance and less severe diarrhea and body weight loss,
but did not improve other signs of naloxone-precipitated
withdrawal (jumping, teeth chattering, paw tremor, whole
body tremor) (Gomes et al., 2013) (Table 3). A bivalent
ligand comprising a µ-receptor agonist (oxymorphone-derived
ligand, oxymorphamine) linked to a δ-receptor antagonist
(naltrindole) by a 21-atom spacer (MDAN-21) was designed
as a putative µ–δ heteromer ligand. This is based on earlier
studies reporting attenuation of morphine-induced side effects
by blocking δ-receptor function (Gendron et al., 2016). MDAN-
21 produced analgesia in the acute heat pain test, but did
not induce acute tolerance, naloxone-precipitated jumping,
and reward (in CPP assay) compared to morphine in mice;
nevertheless, the µ–δ heteromer-selectivity of MDAN-21
action was not shown (Daniels et al., 2005; Lenard et al., 2007)
(Table 3).
To target other putative heteromers, several compounds of
different chemistry have been generated. Examples of bivalent
ligands are MMG22 and MCC22, which exert agonistic action
at µ-receptors and antagonistic activity at various receptors
mediating pain. The former was designed to target µ–mGluR5
heteromers, as it consists of µ-agonist (oxymorphamine)
and mGluR5 antagonist (metoxy-2-methyl-6-(phenylethynyl)-
pyridine) connected by a 22-atom spacer. Compared to morphine
or the individual pharmacophores, MMG22 was more potent,
but similarly efficacious in mouse models of inflammatory, bone
cancer (Akgün et al., 2013), and neuropathic pain (Peterson
et al., 2017). However, as the latter study showed that MMG22
acted at µ-receptors and mGluR5 as separate monomers rather
than heteromers (Peterson et al., 2017), and the examination
of side effects was very limited (Akgün et al., 2013), a rigorous
evaluation of a broad adverse effect spectrum will be essential
to justify the utility of this compound. MCC22 comprises a
µ-agonist (oxymorphamine) and CCR5 antagonist (TAK-220)
linked by a 22-atom spacer, and was designed to act at µ–CCR5
heteromers. Compared to morphine, MCC22 ameliorated tactile
hypersensitivity with similar efficacy, but higher potency and of
longer duration, without inducing tolerance, in a mouse model
of sickle cell disease. The assessment of receptor specificity and
other than tolerance side effects awaits further research (Cataldo
et al., 2018) (Table 2).
Monovalent molecules N-naphthoyl-β-naltrexamine (NNTA)
and N-2′-indolylnaltrexamine (INTA) were developed to target
heteromers containing κ-receptors, probably because κ-receptor
activation does not induce reward. NNTA designed to act at
µ–κ heteromers produced analgesia in acute heat pain test,
little tolerance, and no naloxone-precipitated jumping. It also
did not induce reward at half-maximal analgesic doses, but
exerted strong aversion at maximal analgesic doses (in CPP/CPA
paradigm), which is consistent with the pharmacology of mixed
κ-receptor agonist/µ-receptor antagonist opioid class (Yekkirala
et al., 2011). INTA designed to target µ–κ and/or δ–κ heteromers
did not induce acute analgesic tolerance in heat pain test,
and was not aversive, but produced robust reward (Le Naour
et al., 2014). It is still unclear whether NNTA and INTA exert
the respective heteromer-selective effects, and their aversive or
rewarding properties are clear drawbacks (Table 3).
Multifunctional ligands are designed to interact with two or
more receptors, but heteromers are not necessary their primary
target. The advantages of such multitarget, single compounds
over a co-administration of several, each receptor-selective
ligands, include easier pharmacokinetics and the lack of potential
drug–drug interactions. A known, clinically used example of such
compound is buprenorphine, which is a partial agonist at µ- and
nociceptin/orphanin FQ peptide (NOP) receptors, and a weak
antagonist at κ- and δ-receptors. Buprenorphine is predominately
applied for the treatment of opioid dependency, as it exhibits
ceiling effect for respiratory depression, which diminishes the
likelihood of respiratory arrest, and has reduced abuse liability
(probably due to its partial µ-receptor agonistic activity) and
diminished aversive properties (possibly due to its antagonistic
κ-receptor activity). It appears that the majority of clinical trials
in cancer pain patients were observational, of poor quality, and
with a high risk of bias. Similarly, good quality, randomized
studies in neuropathic pain patients are needed. In randomized
trials of postoperative or osteoarthritis pain, buprenorphine
was concluded to produce fewer respiratory complications, but
equivalent analgesia to other opioids (Davis et al., 2018), although
the reason for the lack of ceiling analgesic effects in contrast
to respiratory depression is unclear, and other studies reported
high rate of drop-out due to nausea/vomiting (Fishman and Kim,
2018). Together, as buprenorphine is successfully used for opioid
maintenance therapy, the evidence for its analgesic superiority
over other opioids in clinical setting appears moderate and more
good quality comparative studies are needed (Davis et al., 2018).
Examples of new multifunctional ligands tested in preclinical
studies are peptides Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-
Bn(CF3)2 (TY027), RCCHM3, and RCCHM6, which exert µ-
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and δ-opioid receptor agonistic and NK1 receptor antagonistic
activity (Figure 4D). In a very comprehensive study, TY027
injected supraspinally, spinally, or intravenously reversed
neuropathy-induced heat and tactile hypersensitivity. In contrast
to morphine, TY027 did not produce analgesic tolerance,
reward (in CPP test), naloxone-precipitated withdrawal
(teeth chattering, wet-dog shakes, diarrhea, weight loss),
did not inhibit gastrointestinal transit (in mice or rats),
and did not cause retching/vomiting (in ferrets), although
the doses were up to 5-fold lower than the most effective
analgesic doses. Additionally, TY027 was shown to act as
opioid receptor agonist and NK1 receptor antagonist in vivo
(Largent-Milnes et al., 2013). RCCHM3 and RCCHM6 were
efficacious in ameliorating neuropathy-induced tactile and
cold hypersensitivity in mice, but the receptor selectivity
and side effects were not examined (Starnowska et al., 2017)
(Table 2).
Additionally, a bifunctional partial agonist at µ- and NOP
receptors, AT-121, has been recently developed. The rationale is
based on earlier studies reporting synergistic analgesic actions
of morphine and NOP receptor agonists, as well as reduced
dopamine release and attenuation of rewarding effects of
µ-agonists by NOP receptor agonists (Toll et al., 2016). In
rhesus monkeys, subcutaneously injected AT-121 did not induce
scratching, but produced comparable to morphine analgesia,
which was reversed by opioid and NOP receptor antagonists in
an acute heat pain test. AT-121 also reversed capsaicin-induced
sensitivity measured by the same test. Unlike oxycodone, it
lacked reinforcing effects in self-administration paradigm, and
partially attenuated reinforcing action of oxycodone. Unlike
heroin, AT-121 at 10 times the analgesic doses did not
compromise respiratory and cardiovascular function (respiration
rate, minute volume, heart rate, mean arterial pressure).
These parameters were also unchanged after injection of
the antagonists, indicating a lack of antagonist-precipitated
withdrawal in AT-121-treated monkeys. Moreover, following
repeated administration (twice daily for 4 weeks), in contrast
to morphine, AT-121 did not produce analgesic tolerance in
the heat pain test (Ding et al., 2018) (Table 3). Although
understandably, the numbers of monkeys per group were low and
the chronic pain could not be examined, these conditions present
some limitations. Additionally, since NOP receptors are very
widely distributed throughout the nervous system and peripheral
tissues, other potential side effects produced by NOP receptor
agonists, including motor disturbance, memory impairment, and
gastrointestinal complications, need to be considered (Mogil and
Pasternak, 2001; Toll et al., 2016).
Together, of all opioid receptor heteromers described in
heterologous systems in vitro, the µ–δ heteromer might be
present and function in vivo. However, more research would be
needed to develop selective ligands, test them in pathological
pain models and in a broad range of side effect tests to
justify the targeting of µ–δ heteromer as improved pain
therapy. Of numerous ligands designed to simultaneously act at
various receptors, TY027 has been thoroughly examined, showed
analgesic efficacy in pathological pain and promising side effect
profile.
µ-RECEPTOR SPLICE VARIANTS
Alternative splicing is a genetic regulation that takes place
during gene expression when particular exons (transcriptional
sequences) of a gene are either included or excluded from the
final mRNA, which may result in generation of multiple protein
isoforms (Black, 2003). Among opioid receptors, the alternative
splicing of µ-receptor coding exons has been extensively
examined and the generation of multiple splice variants in mice,
rats, and humans has been revealed. In addition to classic
full-length, seven-transmembrane (7TM) domain µ-receptor
variants, there are also exon 1-associated truncated 1TM domain
variants and exon 11-associated truncated 6TM domain variants.
Depending on the species, two to five 1TM domain and 6TM
domain variants have been described (Pasternak and Pan, 2013).
Several of these variants have been detected in the mouse brain,
spinal cord, and DRG at the mRNA level (Pasternak and Pan,
2013; Wieskopf et al., 2014), and some of them were examined
by immunohistochemistry, but difficulties associated with the
specificity of antibodies preclude the convincing evidence on
their expression at the protein level (Pasternak and Pan, 2013).
It has been suggested that 1TM domain variants do not bind
ligands, but function as molecular chaperones that facilitate
expression of the 7TM domain µ-receptor and thereby enhance
morphine analgesia. In contrast, 6TM domain variants appear
to possess distinct pharmacology characterized by the use of
a compound iodobenzoylnaltrexamide (IBNtxA) (Figure 4E).
Radiolabeled IBNtxA-binding sites were detected in the brain
membrane homogenates in wild-type mice and mice lacking
7TM domain µ-, δ-, and κ-opioid receptors, but were absent in
exon 11 knockout mice (Majumdar et al., 2011). Systemically
applied IBNtxA diminished spontaneous inflammatory pain and
mechanical hypersensitivity in inflammatory and neuropathic
pain models in wild-type mice, whereas the effects in the
latter two models were absent in exon 11-lacking mice
(Wieskopf et al., 2014). Compared to morphine, IBNtxA at
analgesic or higher doses exerted lesser constipation, and
did not produce respiratory depression, naloxone-precipitated
jumping, and CPP reward (Majumdar et al., 2011) (Table 2).
Experiments in µ-receptor knockout mice reconstituted with
6TM domain variants confirmed their contribution to IBNtxA-
induced analgesia (in the acute heat pain test) (Lu et al., 2018). It
is still unclear what cellular mechanisms underlie analgesic effects
and improved side effect profile of 6TM domain variants, and
whether these variants are functional in humans. The complexity
of this system is additionally implied by animal studies describing
excitatory cellular actions of 6TM domain variants and enhanced
heat sensitivity following repetitive injections of IBNtxA in naïve




Enhancing the activity of endogenous opioid peptides as
natural agonists of opioid receptors represents an intrinsic pain
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control. Opioid peptides, including β-endorphin, enkephalins
and dynorphins are expressed in neurons in pain-relevant
regions of the central or peripheral nervous system as well
as in immune cells accumulating in peripheral painful tissue
(Fields, 2004; Stein and Machelska, 2011). Hence, targeting
endogenous opioids at the site of their native expression may
diminish the risk of off-site, unphysiological actions. Electrical
stimulation of periventricular/periaqueductal gray matter and
thalamus, or activation of immune cells in peripheral inflamed
tissue (by surgery-related stress or local application of opioid
peptide-releasing agents) alleviates pathological pain involving
endogenous opioids in humans (Stein et al., 1993; Bittar
et al., 2005; Likar et al., 2007). Notably, immune cell-derived
opioid peptides exerted additive/synergistic analgesic action with
peripherally (intra-articularly) applied morphine in patients
with postoperative pain (Stein et al., 1996; Likar et al., 2004),
which may be related to the activation of leukocyte opioid
receptors (Celik et al., 2016). Nonetheless, opioid peptides
are rapidly enzymatically degraded, and the best characterized
enzymes are aminopeptidase N (APN; also known as CD13) and
neutral endopeptidase (NEP; also known as neprilysin, CD10,
or enkephalinase). Among opioid peptides, the predominant
substrates of APN and NEP are Met- and Leu-enkephalin, but
dynorphin A 1-17 can also be inactivated. Both enzymes are
functional in the CNS, peripheral nerves, and immune cells, and
their blockade prevented opioid peptide degradation (Bourgoin
et al., 1986; Le Guen et al., 2003; Schreiter et al., 2012). Since the
actions of both peptidases are complementary, their concomitant
blockade is most efficient, which led to the development of dual
APN and NEP inhibitors, now known as dual enkephalinase
(DENK) inhibitors (Figure 5A). Over the last four decades,
numerous DENK inhibitors have been synthetized and found
to alleviate inflammatory, neuropathic, abdominal, cancer, and
postoperative pain, when applied intravenously, orally, or into
inflamed tissue in animal models (Roques et al., 2012; Schreiter
et al., 2012). Compared to morphine, DENK inhibitors in
analgesic or higher doses produced no or less severe side effects,
including tolerance, naloxone-precipitated withdrawal, reward
(CPP, ICSS), respiratory depression, and constipation (Noble
and Roques, 2007). Within the last decade, DENK inhibitors
developed by Pharmaleads (Paris, France) for the treatment
of postoperative pain (PL37) or neuropathic and ocular pain
(PL265) entered clinical trials, but the data are not yet available
(Roques et al., 2012)2 (Table 1).
Gene Therapy
Gene therapy (or gene transfer) is based on the introduction
of DNA or RNA encoding a protein of interest, and offers
a possibility of the protein long-term expression in native
tissue. For in vivo delivery of genes encoding enkephalin
precursor proenkephalin (PENK) or β-endorphin precursor
proopiomelanocortin (POMC), different vectors have been
used, including plasmids, non-replicating adenoviruses, adeno-
associated viruses, and herpes simplex virus (HSV), as well
as non-plasmid and non-viral DNA vectors (e.g., MIDGE;
2http://www.pharmaleads.com/
minimalistic, immunologically defined gene expression vector).
There are numerous preclinical studies, in which these PENK-
or POMC-encoding vectors were applied intramuscularly, on
the spinal cord, intra-articularly, or into the skin/subcutaneous
tissue, which resulted in enhanced expression of the respective
peptides (Met/Leu-enkephalin or β-endorphin) in the
corresponding tissue. Consequently, these treatments led to
attenuation of mechanical and heat hypersensitivity in models
of inflammatory, neuropathic, or cancer pain, mediated by
spinal or peripheral opioid receptors; these analgesic effects were
rather modest, but in some cases persisted for several weeks
(Machelska et al., 2009; Simonato et al., 2013; Goss et al., 2014;
Hu et al., 2016; Klein et al., 2018). Since this strategy targets
peripheral and spinal cord tissue, the opioid side effects mostly
mediated in the brain are not anticipated, but this has not been
verified. Compared to non-viral vectors, viral vectors have higher
transfection efficacy, which is attributed to the natural ability of
viruses to infect and express their genes in host cells. However,
viral vectors can potentially cause toxicity and inflammation,
which depends on treatment conditions (e.g., dosing, route
of application), although based on so far available data, HSV
vectors inoculated into the skin are predicted to be safe (Wolfe
et al., 2009; Simonato et al., 2013; Goss et al., 2014). The first
phase 1 clinical trial testing this strategy employed HSV-based
vector encoding human PENK injected intradermally (into the
pain-corresponding dermatomes) in terminally ill patients with
intractable cancer pain. The treatment was well tolerated and
no serious adverse events were observed. Over the 4-month
follow-up, the treatment-emergent adverse effects (injection
site erythema and pruritus, and body temperature elevation)
were transient and judged of mild severity. The study was very
small (four or fewer patients per group), not blinded and not
placebo-controlled, but also reported a dose-related decrease of
pain (up to 4 weeks post-treatment) as the secondary outcome
(Fink et al., 2011). A phase 2, randomized, double-blind,
placebo-controlled, multicenter study testing HSV-encoding
PENK in patients with intractable malignant pain has been
completed, but the data are not yet released (ClinicaleTrials.gov
NCT01291901) (Table 1). Based on the corresponding pre-
clinical studies it is anticipated that HSV-encoding PENK is
taken up by cutaneous terminals of peripheral sensory neurons
and axonally transported to their cell bodies in DRG, where
PENK is processed to enkephalins. The enkephalins can be
then transported toward peripheral and central DRG neuron
terminals, released and respectively activate peripheral and
spinal opioid receptors to provide analgesia (Antunes Bras et al.,
1998, 2001; Goss et al., 2001; Klein et al., 2018) (Figure 5B).
Similar strategy can also be used to enhance expression of opioid
receptors. For example, HSV-encoding µ-receptors applied
to mouse hind paw elevated µ-receptor-immunoreactivity in
epidermal skin fibers, DRG cells, and dorsal horn spinal cord,
alleviated basal mechanical hypersensitivity, and enhanced
analgesic effects of morphine and peripherally acting loperamide
injected systemically in a neuropathic pain model (Table 2).
Surprisingly and not clarified yet, combined treatment with
HSV-encoding µ-receptors and HSV-encoding PENK was
ineffective (Klein et al., 2018).
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FIGURE 5 | Strategies for safer pain control – targeting endogenous opioid peptides. (A) Prevention of opioid peptide degradation. (1) Opioid peptides, including
enkephalins (ENK) are degraded by APN and NEP expressed on neurons (central and peripheral) and immune cells in inflamed tissue. (2) DENK inhibitors block APN
and NEP, and prevent ENK degradation to locally alleviate pain. (B) Gene transfer to enhance opioid peptide production in native tissue. As an example, HSV vector
encoding ENK precursor PENK injected into peripheral tissue is taken up by peripheral terminals of dorsal root ganglion (DRG) neurons and transported to their cell
bodies in DRG (1), where PENK is processed to ENK (2). ENK is then transported to peripheral and central DRG neuron terminals (3), released, and respectively
activates peripheral and spinal opioid receptors to produce analgesia.
OTHER APPROACHES
Abuse-Deterrent Opioid Formulations
Currently clinically used opioids have been modified to obtain
abuse-deterrent formulations, and several of such substances
have been approved by the Food and Drug Administration
(Becker and Fiellin, 2017). The general aim was to make these
new formulations difficult to inhale or inject, and to get a high
from. This has been attempted by means of physical or chemical
barriers to hinder crushing, chewing, or solubilization of pills, as
in case of modifications of morphine (MorphaBond ER, Arymo
ER), oxycodone (OxyContin, RoxyBond, Xtampza ER), and
hydrocodone (Vantrela ER, Hyslinga ER). Alternatively, opioid
receptor agonists were combined with antagonists, as in case
of Embeda (morphine and naltrexone), Troxyca ER (oxycodone
and naltrexone), or Targiniq ER (oxycodone and naloxone)
(Becker and Fiellin, 2017; Salwan et al., 2018). However, these
strategies have not proved successful in preventing opioid abuse.
To overcome the obstacles associated with hindering the misuse
of these formulations they were taken at higher doses or replaced
with other opioids having a higher abuse liability such as heroin
or fentanyl (Cicero and Ellis, 2015; Becker and Fiellin, 2017;
Curfman et al., 2018; Salwan et al., 2018).
Agonists With Low Rate CNS Entry
Nektar Therapeutics (San Francisco, CA, United States) has
synthetized and been testing a compound NKTR-181, a
µ-receptor agonist with a low rate influx across the BBB,
proposing that such substance should have lower abuse potential
compared to drugs with rapid CNS entry. The slow CNS entry
has been achieved by addition of a polyethylene glycol functional
group to morphine-like (morphinan) pharmacophore. NKTR-
181 produced analgesia in naïve animals in acute heat pain test
and in acetic acid-induced writhing model, but the µ-receptor-
selectivity and the action site (central, peripheral) have not
been examined. Its side effect profile was improved compared
to oxycodone, although at the most effective analgesic doses
NKTR-181 induced mild muscle rigidity and motor impairment.
Compared to cocaine and oxycodone, it did not produce reward
in self-administration paradigm (Miyazaki et al., 2017) (Table 3).
In healthy, non-physically dependent recreational opioid users,
single oral application of NKTR-181 (in doses used in ongoing
phase 3 trials) induced significantly lower drug liking effects
(indicative of lower abuse potential) and smaller changes in the
pupil diameter (indicative of less robust CNS actions) relative to
oxycodone. Still, the effects of the highest NKTR-181 dose used
were significantly higher vs. placebo (Webster et al., 2018). The
compound is considered to be resistant to physical or chemical
tampering, albeit the data were not shown (Miyazaki et al., 2017),
and the possibility of taking it at high doses to achieve high
CNS levels cannot be excluded, as in case of abuse-deterrent
opioids. The company sponsored completed phase 2 trial in
patients with osteoarthritis (NCT02367820) and phase 3 trial
in patients with chronic low back pain (NCT02362672; both at
ClinicalTrials.gov), but the peer reviewed data are not available
yet (Table 1).
Endomorphin Analogs
Endomorphin-1 and endomorphin-2 are additional endogenous
opioid peptides, although (in contrast to endorphins,
enkephalins, and dynorphins) their precursor has not been
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identified so far (Zadina et al., 1997). Both endomorphins
are highly selective at µ-receptors and exerted analgesia with
reduced side effects relative to conventional opioids in some
preclinical studies. Due to their poor metabolic stability,
numerous endomorphin analogs with potentially improved
pharmacological properties have been developed (Gu et al., 2017).
Example is a recently characterized cyclized, D-amino acid-
containing endomorphin 1 peptide analog termed analog 4 or
ZH853 (Tyr-c-[D-Lys-Trp-Phe-Glu]-Gly-NH2). This compound
alleviated heat and mechanical hypersensitivity in models of
neuropathic, inflammatory, and postoperative pain following
spinal or intravenous injections. Relative to morphine, the
analog 4-induced analgesia was equally effective but longer-
lasting (Feehan et al., 2017). Moreover, in contrast to morphine,
analog 4 produced lesser analgesic tolerance, no motor
impairment, respiratory depression, and reward (in CPP and
self-administration paradigms), and did not induce spinal glia
activation (Zadina et al., 2016), although side effects were mostly
tested using similar or lower than analgesic doses (Feehan
et al., 2017) (Table 2). Whereas the results appear promising,
considering that the compound crosses the BBB and activates
µ-receptors in the brain (Zadina et al., 2016), it will be important
to elucidate the mechanistic basis for its improved side effect
profile.
Allosteric Modulators
Allosteric modulators are ligands that bind the allosteric site
of the receptor (i.e., the site that does not bind orthosteric
ligands such as endogenous and standard exogenous ligands)
and can modulate (positively or negatively) the effect of the
orthosteric ligand without eliciting activity on its own. For
example, it is anticipated that positive allosteric modulators will
enhance the activity of endogenous opioid peptides, maintain
their temporal and spatial action, and potentially limit the off-
target adverse effects. Although several such compounds have
been characterized in vitro, their utility in vivo is yet to be
determined (Remesic et al., 2017).
CONCLUSION
Conventional opioids are the most effective painkillers, but
they also produce adverse affects. Additionally, their prolonged
use leads to addiction, which limits the effectiveness of pain
therapy and has resulted in a worldwide opioid epidemic
(Abdel-Hamid et al., 2016; Novak et al., 2016; Volkow et al.,
2018). Therefore, the search for opioids with improved side
effect profile and low abuse liability is undisputed. Several
novel treatments targeting peripheral κ-receptors (asimadoline,
CR845), endogenous opioid peptides (DENK inhibitors, HSV-
PENK), and agonist with a low rate CNS entry (NKTR-181)
are under development and are tested in clinical trials, but
not all results are available yet (Table 1) and it remains to
be seen whether they enter clinical practice. The G protein-
biased agonism as a safer pain therapy needs to be verified,
since opioid-induced adverse actions are mediated by G proteins
(Figure 2A), and there are increasing numbers of studies that
report biased agonist-induced constipation, sedation, respiratory
depression, and addiction (Inui, 2012; Soergel et al., 2014; Altarifi
et al., 2017; Hill et al., 2018) (Tables 1, 3). Encouragingly,
there are several new opioids examined in preclinical studies,
which are comprehensively characterized in various pathological
pain models and methods assessing a wide spectrum of side
effects, and show promising results. They include an agonist
sensitive to low pH characteristic of painful tissue (NFEPP),
ligands targeting multiple receptors (TY027) or µ-receptor splice
variants (IBNtxA), and endomorphin-1 analog (analog 4 or
ZH853) (Table 2). Nevertheless, several aspects are still open
such as mechanistic basis of analgesia and improved side effect
profile (IBNtxA, endomorphin-1 analog), the need for replication
of the initial findings (NFEPP, TY027), and examination of their
clinical efficacy. Although there are no preclinical assays that
ideally reflect pain in humans, the pathological pain models
involving tissue damage and lasting for days or weeks (Table 2)
closer resemble clinical conditions than the tests inducing pain
lasting for seconds in naïve animals (Mogil, 2009) (Table 3).
Additionally, even though there is an increasing awareness of
the importance of the rigorous study design and performance,
including blinding, randomization, and sample size estimation
(Kilkenny et al., 2010; Berg, 2017), many animal studies still
do not adhere to these requirements (Tables 2, 3). It is thus
critical that all these aspects are considered when the clinical
translation of preclinical studies is judged. Finally, it is crucial to
recognize the multifactorial biopsychosocial etiology of chronic
pain and that it requires a multidisciplinary management
comprising not only pharmacologic, but also psychological, and
physiotherapeutic approaches (Scascighini et al., 2008; Stein and
Kopf, 2009). Pharmacologic treatment alone is insufficient and
will always carry a risk of unwanted behaviors, as seen by the
shifting trends in pain management and the addiction landscape
toward alternative opioid (e.g., loperamide) and non-opioid
(e.g., gabapentin, pregabalin), but also potentially dangerous
medications (Throckmorton et al., 2018).
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